EPCAM and gastric neoplasm: Due to high-level expression on different epithelial tumours, EpCAM was considered as an interesting target for anticancer therapy.7 The cell surface protein is known to be overexpressed in >90% of gastric tumours.7 In case of peritoneal application for PC, catumaxomab exclusively binds to epithelial tumour cells and not to the EpCAM-negative mesothelial cells of the peritoneal surface.